Dynorphin and the pathophysiology of drug addiction

Pharmacology and Therapeutics

Volumn 116, Issue 2, 2007, Pages 306-321

  Shippenberg, T S ^a   Zapata, A ^a   Chefer, V I ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Opioid receptor; Dopamine; Drug and alcohol addiction; Dynorphin; Glutamate

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; ACETAMIDE DERIVATIVE; ALCOHOL; COCAINE; DOPAMINE; DYNORPHIN; ENKEPHALIN; GLUTAMIC ACID; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; PRODYNORPHIN; SALVINORIN A;

ALCOHOLISM; ANHEDONIA; ANXIETY DISORDER; BEHAVIOR CHANGE; BRAIN REGION; DOPAMINERGIC TRANSMISSION; DRUG DEPENDENCE; DYSPHORIA; GABAERGIC SYSTEM; GENE CONTROL; GENE EXPRESSION; HUMAN; IMMUNOREACTIVITY; LIMBIC CORTEX; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM; WITHDRAWAL SYNDROME;

ALCOHOLISM; ANIMALS; BEHAVIOR, ADDICTIVE; BRAIN; COCAINE; COCAINE-RELATED DISORDERS; DYNORPHINS; ETHANOL; HUMANS; RECEPTORS, OPIOID, KAPPA; SUBSTANCE-RELATED DISORDERS; UP-REGULATION;

EID: 34648832260     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2007.06.011     Document Type: Review

References (222)

1. Alvarez-Bolado G., Fairen A., Douglass J., and Naranjo J.R. Expression of the prodynorphin gene in the developing and adult cerebral cortex of the rat: an in situ hybridization study. J Comp Neurol 300 (1990) 287-300
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. (4th ed.). (1994), American Psychiatric Press, Washington, DC
3. Bals-Kubik R., Herz A., and Shippenberg T.S. Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated. Psychopharmacology 98 (1989) 203-206
4. Bals-Kubik R., Ableitner A., Herz A., and Shippenberg T.S. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther 264 (1993) 489-495
5. Baker D.A., McFarland K., Lake R.W., Shen H., Tang X.-C., Toda S., et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci 6 (2003) 743-749
6. Barr A.M., Markou A., and Phillips A.G. A "crash" course on psychostimulant withdrawal as a model of depression. Trends Pharmacol Sci 23 (2002) 475-490
7. Beadles-Bohling A.S., and Wiren K.M. Alteration of kappa-opioid receptor system expression in distinct brain regions of a genetic model of enhanced ethanol withdrawal severity. Brain Res 1046 (2005) 77-89
8. Beardsley P.M., Howard J.L., Shelton K.L., and Carroll F.I. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by foot shock stressors vs. cocaine primes and its antidepressant-like effects in rats. Psychopharmacology 183 (2005) 118-126
9. Berendse H.W., Galis-de Graaf Y., and Groenewegen H.J. Topographical organization and relationship with ventral striatal compartments of prefrontal corticostriatal projections in the rat. J Comp Neurol 316 (1992) 314-347
10. Bhushan R.G., Sharma S.K., Xie Z., Daniels D.J., and Portoghese P.S. A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers. J Med Chem 47 (2004) 2969-2972
11. Bodnar R.J., and Klein G.E. Endogenous opiates and behavior. Peptides 26 (2005) 2629-2711
12. Brandon C.L., and Steiner H. Repeated methylphenidate treatment in adolescent rats alters gene regulation in the striatum. Eur J Neurosci 18 (2003) 1584-1592
13. Breiter H.C., Gollub R.L., Weisskoff R.M., Kennedy D.N., Makris N., Berke J.D., et al. Acute effects of cocaine on human brain activity and emotion. Neuron 19 3 (1997) 591-611
14. Broadbear J.H., Negus S.S., Butelman E.R., de Costa B.R., and Woods J.H. Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay. Psychopharmacology (Berl) 115 3 (1994) 311-319
15. Brodie M.S., Pesold C., and Appel S.B. Ethanol directly excites dopaminergic ventral tegmental area reward neurons. Alcohol Clin Exp Res 23 (1999) 1848-1852
16. Capriles N., Rodaros D., Sorge R.E., and Stewart J. A role for the prefrontal cortex in stress- and cocaine-induced reinstatement of cocaine seeking in rats. Psychopharmacology 168 (2003) 66-74
17. Carlezon Jr. W.A., Thome J., Olson V.G., Lane-Ladd S.B., Brodkin E.S., Hiroi N., et al. Regulation of cocaine reward by CREB. Science 282 (1998) 2272-2275
18. Carlezon Jr. W.A., Beguin C., DiNieri J.A., Baumann M.H., Richards M.R., Todtenkopf M.S., et al. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 16 1 (2006) 440-447
19. Carroll F.I., Thomas J.B., Dykstra L.A., Granger A.L., Allen R.M., Howard J.L., et al. Pharmacological properties of JDTic: a novel k-opioid receptor antagonist. Eur J Pharmacol 501 (2004) 111-119
20. Cenci M.A., and Bjorklund A. Transection of corticostriatal afferents reduces amphetamine- and apomorphine-induced striatal Fos expression and turning behaviour in unilaterally 6-hydroxydopamine-lesioned rats. Eur J Neurosci 5 (1993) 1062-1107
21. Chavkin C., James I.F., and Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 215 (1982) 413-415
22. Chefer V.I., Moron J.A., Hope B., Rea W., and Shippenberg T.S. Kappa-opioid receptor activation prevents alterations in mesocortical dopamine neurotransmission that occur during abstinence from cocaine. Neuroscience 101 (2000) 619-627
23. Chefer V.I., Czyzyk T., Bolan E.A., Moron J., Pintar J.E., and Shippenberg T.S. Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine. J Neurosci 25 (2005) 5029-5037
24. Chen A.C., LaForge K.S., Ho A., McHugh P.F., Kellogg S., Bell K., et al. Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse. Am J Med Genet 114 (2002) 429-435
25. Chrobak J.J., and Napier T.C. Opioid and GABA modulation of accumbens-evoked ventral pallidal activity. J Neural Transm 93 (1993) 123-143
26. Cole R.L., Konradi C., Douglass J., and Hyman S.E. Neuronal adaptation to amphetamine and dopamine: molecular mechanisms of prodynorphin gene regulation in rat striatum. Neuron 14 (1995) 813-823
27. Collins S.L., D'Addario C., and Izenwasser S. Effects of kappa-opioid receptor agonists on long-term cocaine use and dopamine neurotransmission. Eur J Pharmacol 426 (2001) 25-34
28. Corbett A.D., Paterson S.J., McKnight A.T., Magnan J., and Kosterlitz H.W. Dynorphin and dynorphin are ligands for the kappa-subtype of opiate receptor. Nature 299 (1982) 79-81
29. Crawford C.A., McDougall S.A., Bolanos C.A., Hall S., and Berger S.P. The effects of the kappa agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviors and Fos immunoreactivity. Psychopharmacology 120 (1995) 392-399
30. Cryan J.F., Markou A., and Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23 (2002) 238-245
31. Dahl J.P., Weller A.E., Kampman K.M., Oslin D.W., Lohoff F.W., Ferraro T.N., et al. Confirmation of the association between a polymorphism in the promoter region of the prodynorphin gene and cocaine dependence. Am J Med Genet 139 (2005) 106-108
32. Daunais J.B., Roberts D.C., and McGinty J.F. Cocaine self-administration increases preprodynorphin, but not c-fos, mRNA in rat striatum. NeuroReport 4 (1993) 543-546
33. De Vries T.J., Schoffelmeer A.N., Binnekade R., Mulder A.H., and Vanderschuren L.J. Drug-induced reinstatement of heroin- and cocaine-seeking behaviour following long-term extinction is associated with expression of behavioural sensitization. Eur J Neurosci 10 (1998) 3565-3571
34. Diana M., Pistis M., Carboni S., Gessa G.L., and Rossetti Z.L. Profound decrement of mesolimbic dopaminergic neuronal activity during ethanol withdrawal syndrome in rats: electrophysiological and biochemical evidence. Proc Natl Acad Sci 90 (1993) 7966-7969
35. Diana M., Pistis M., Muntoni A., and Gessa G. Mesolimbic dopaminergic reduction outlasts ethanol withdrawal syndrome: evidence of protracted abstinence. Neuroscience 71 (1996) 411-415
36. Di Benedetto M., D'addario C., Candeletti S., and Romualdi P. Chronic and acute effects of 3,4-methylenedioxy-N-methylamphetamine ("ecstasy") administration on the dynorphinergic system in the rat brain. Mol Neurosci 137 (2006) 187-196
37. Di Chiara G., and Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci 85 (1988) 5274-5278
38. Di Chiara G., Bassareo V., Fenu S., De Luca M.A., Spina L., Cadoni C., et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 47 Suppl 1 (2004) 227-241
39. Di Ciano P., and Everitt B.J. Dissociable effects of antagonism of NMDA and AMPA/KA receptors in the nucleus accumbens core and shell on cocaine-seeking behavior. Neuropsychopharmacology 25 3 (2001) 341-360
40. Di Ciano P., and Everitt B.J. Direct interactions between the basolateral amygdala and nucleus accumbens core underlie cocaine-seeking behavior by rats. J Neurosci 24 (2004) 7167-7173
41. Di Ciano P., and Everitt B.J. Neuropsychopharmacology of drug seeking: insights from studies with second-order schedules of drug reinforcement. Eur J Pharmacol 526 (2005) 186-198
42. Doyon W.M., Howard E.C., Shippenberg T.S., and Gonzales R.A. Kappa-opioid receptor modulation of accumbal dopamine concentration during operant ethanol self-administration. Neuropharmacology 51 3 (2006) 487-496
43. Endoh T., Matsuura H., Tanaka C., and Nagase H. Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther 316 (1992) 30-42
44. Everitt B.J., and Robbins T.W. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8 (2005) 1481-1489
45. Everitt B.J., and Wolf M.E. Dopamine release in the dorsal striatum during cocaine-seeking behavior under the control of a drug-associated cue. J Neurosci 22 14 (2002) 6247-6253
46. Fadda P., Tronci C., Colombo G., and Fratta W. Differences in the opioid system in selected brain regions of alcohol-preferring and alcohol-nonpreferring rats. Alcohol Clin Exp Res 23 (1999) 1296-1305
47. Fagergren P., Smith H.R., Daunais J.B., Nader M.A., Porrino L.J., and Hurd Y.L. Temporal upregulation of prodynorphin mRNA in the primate striatum alter cocaine self-administration. Eur J Neurosci 17 (2003) 2212-2218
48. Gambardella A., Manna I., Labate A., Chifari R., Sera P., LaRussa A., et al. Prodynorphin gene promoter polymorphism and temporal lobe epilepsy. Epilepsia 44 (2003) 1225-1256
49. Gawin F.H. Cocaine addiction: psychology and neurophysiology. Science 251 (1991) 1580-1586
50. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J., et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250 (1990) 1429-1432
51. Gerfen C.R., McGinty J.F., and Young W.S. Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J Neurosci 11 (1991) 1016-1031
52. Glick S.D., Maisonneuve I.M., and Raucci J. Archer S., Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res 681 (1995) 147-152
53. Gong W., Neill D., and Justice Jr. J.B. Conditioned place preference and locomotor activation produced by injection of psychostimulants into ventral pallidum. Brain Res 707 (1996) 64-74
54. Gong W., Neill D., and Justice Jr. J.B. 6-Hydroxydopamine lesion of ventral pallidum blocks acquisition of place preference conditioning to cocaine. Brain Res 754 (1997) 103-112
55. Gray A.M., Rawls S.M., Shippenberg T.S., and McGinty J.F. The kappa-opioid agonist, U-69593, decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum. J Neurochem 73 3 (1999) 1066-1074
56. Graybiel A.M. Neurotransmitters and neuromodulaters in the basal ganglia. Trends Neurosci 13 (1990) 244-254
57. Graybiel A.M. The basal ganglia: learning new tricks and loving it. Curr Opin Neurobiol 15 6 (2005) 638-644
58. Groenewegen H.J., Berendse H.W., and Haber S.N. Organization of the output of the ventral striatopallidal system in the rat: ventral pallidal efferents. Neuroscience 57 (1993) 113-142
59. Gross R.A., and MacDonald R.L. Dynorphin A selectively reduces a large transient (N-type) calcium current of mouse dorsal root ganglion neurons in cell culture. Proc Natl Acad Sci 84 (1987) 5469-5473
60. Grudt T.J., and Williams J.T. Kappa-opioid receptors also increase potassium conductance. Proc Natl Acad Sci 90 (1993) 11429-11432
61. Gulya K., Orpana A.K., Sikela J.M., and Hoffman P.L. Prodynorphin and vasopressin mRNA levels are differentially affected by chronic ethanol ingestion in the mouse. Mol Brain Res 20 (1993) 1-8
62. Haber S.N., Fudge J.L., and McFarland N.R. Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J Neurosci 20 (2000) 2369-2382
63. Heidbreder C.A., and Shippenberg T.S. U-69593 prevents cocaine sensitization by normalizing basal accumbens dopamine. NeuroReport 5 (1994) 1797-1800
64. Heidbreder C.A., Goldberg S.R., and Shippenberg T.S. The kappa-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat. Brain Res 616 (1993) 335-338
65. Heidbreder C.A., Babovic-Vuksanovic D., Shoaib M., and Shippenberg T.S. Development of behavioral sensitization to cocaine: influence of kappa opioid receptor agonists. J Pharmacol Exp Ther 275 (1995) 150-163
66. Heidbreder C.A., Thompson A.C., and Shippenberg T.S. Role of extracellular dopamine in the initiation and long-term expression of behavioral sensitization to cocaine. J Pharmacol Exp Ther 278 (1996) 182-192
67. Heijna M.H., Bakker J.M., Hogenboom F., Mulder A.H., and Schoffelmeer A.N. Opioid receptors and inhibition of dopamine-sensitive adenylate cyclase in slices of rat brain regions receiving a dense dopaminergic input. Eur J Pharmacol 229 (1992) 197-202
68. Heimer L., and Van Hoesen G.W. The limbic lobe and its output channels: implications for emotional functions and adaptive behavior. Neurosci Biobehav Rev 30 2 (2006) 126-147
69. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology 129 (1997) 99-111
70. Heyliger S.O., Jackson C., Rice K.C., and Rothman R.B. Opioid peptide receptor studies: 10. Nor-BNI differentially inhibits kappa receptor agonist-induced G-protein activation in the guinea pig caudate: further evidence of kappa receptor heterogeneity. Synapse 34 4 (1999) 256-265
71. Hill M.P., and Brotchie J.M. Modulation of glutamate release by a kappa-opioid receptor agonist in rodent and primate striatum. Eur J Pharmacol 281 (1995) R1-R2
72. Hill M.P., and Brotchie J.M. Control of glutamate release by calcium channels and kappa-opioid receptors in rodent and primate striatum. Br J Pharmacol 127 (1999) 275-283
73. Hjelmstad G.O., and Fields H.L. Kappa opioid receptor inhibition of glutamatergic transmission in the nucleus accumbens shell. J Neurophysiol 85 (2001) 1153-1158
74. Holter S.M., Henniger M.S., Lipkowski A.W., and Spanagel R. Kappa-opioid receptors and relapse-like drinking in long-term ethanol-experienced rats. Psychopharmacology 153 (2000) 93-102
75. Horan P.J., de Costa B.R., Rice K., Haaseth R.C., Hruby V.J., and Porreca F. Differential antagonism of bremazocine- and U69,593-induced antinociception by quadazocine: further functional evidence of opioid kappa receptor multiplicity in the mouse. J Pharmacol Exp Ther 266 (1993) 926-933
76. Hurd Y.L. Differential messenger RNA expression of prodynorphin and proenkephalin in the human brain. Neuroscience 72 (1996) 767-783
77. Hurd Y.L., and Herkenham M. Molecular alterations in the neostriatum of human cocaine addicts. Synapse 13 4 (1993) 357-369
78. Hyman S.E., Malenka R.C., and Nestler E.J. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 29 (2006) 565-598
79. Hyytia P. Involvement of mu-opioid receptors in alcohol drinking by alcohol-preferring AA rats. Pharmacol Biochem Behav 45 (1993) 697-701
80. Ito R., Dalley J.W., Robbins T.W., and Everitt B.J. Dopamine release in the dorsal striatum during cocaine-seeking behavior under the control of a drug-associated cue. J Neurosci 22 (2002) 6247-6253
81. Jamensky N.T., and Gianoulakis C. Content of dynorphins and kappa-opioid receptors in distinct brain regions of C57BL/6 and DBA/2 mice. Alcohol Clin Exp Res 21 8 (1997) 1455-1464
82. Jones R.M., and Portoghese P.S. 5′-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist. Eur J Pharmacol 12,396 1 (2000) 49-52
83. Jordan B.A., and Devi L.A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399 (1999) 697-700
84. Kalivas P.W., and Duffy P. Time course of extracellular dopamine and behavioral sensitization to cocaine: I. Dopamine axon terminals. J Neurosci 13 (1993) 266-275
85. Kalivas P.W., and Volkow N.D. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 162 8 (2005) 1403-1413
86. Kalivas P.W., Volkow N., and Seamans J. Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission. Neuron 45 5 (2005) 647-650
87. Klitenick M.A., Deutch A.Y., Churchill L., and Kalivas P.W. Topography and functional role of dopaminergic projections from the ventral mesencephalic tegmentum to the ventral pallidum. Neuroscience 50 (1992) 371-386
88. Koob G.F. Allostatic view of motivation: implications for psychopathology. Nebr Symp Motiv 50 (2004) 1-18
89. Koob G.F., and Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 278 (1997) 52-58
90. Kosterlitz H.W., Corbett A.D., and Paterson S.J. Opioid receptors and ligands. NIDA Res Monogr 95 (1989) 159-166
91. Kovacs K.M., Szakall I., O'Brien D., Wang R., Vinod K.Y., Saito M., et al. Decreased oral self-administration of alcohol in [kappa]-opioid receptor knock-out mice. Alcohol Clin Exp Res 29 (2005) 730-738
92. Kuzmin A.V., Semenova S., Gerrits M.A., Zvartau E.E., and Van Ree J.M. Kappa-opioid receptor agonist U50, 488H modulates cocaine and morphine self-administration in drug-naïve rats and mice. Eur J Pharmacol 321 (1997) 265-271
93. 3H]U-69593 a highly selective ligand for the opioid kappa receptor. Eur J Pharmacol 109 (1985) 281-284
94. Lindholm S., Ploj K., Franck J., and Nylander I. Repeated ethanol administration induces short- and long-term changes in enkephalin and dynorphin tissue concentrations in rat brain. Alcohol 22 (2000) 165-171
95. Lindholm S., Werme M., Brene S., and Franck J. The selective kappa-opioid receptor agonist U50, 488H attenuates voluntary ethanol intake in the rat. Behav Brain Res 120 2 (2001) 137-146
96. Liu-Chen L.Y. Agonist-induced regulation and trafficking of kappa opioid receptors. Life Sci 75 (2004) 511-536
97. Mague S.D., Pliakas A.M., Todtenkopf M.S., Tomasiewicz H.C., Zhang Y., Stevens Jr. W.C., et al. Antidepressant-like effects of-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305 (2003) 323-330
98. Maneuf Y.P., Mitchell I.J., Crossman A.R., Woodruff G.N., and Brotchie J.M. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Res 683 (1995) 102-108
99. Mansour A., Burke S., Pavlic R.J., Akil H., and Watson S.J. Immunohistochemical localization of the cloned kappa 1 receptor in the rat CNS and pituitary. Neuroscience 71 (1996) 671-690
100. Margolis E.B., Hjelmstad G.O., Bonci A., and Fields H.L. Kappa-opioids agonists directly inhibit midbrain dopaminergic neurons. J Neurosci 23 (2003) 9981-9986
101. Margolis E.B., Lock H., Chefer V.I., Shippenberg T.S., and Hjelmstad G.O. Kappa-opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc Natl Acad Sci 103 (2006) 2938-2942
102. Marinelli P.W., Kiianmaa K., and Gianoulakis C. Opioid propeptide mRNA content and receptor density in the brains of AA and ANA rats. Life Sci 66 (2000) 1915-1927
103. Markou A., Hauger R.L., and Koob G.F. Desmethylimipramine attenuates cocaine withdrawal in rats. Psychopharmacology 109 (1992) 305-314
104. Mateo Y., Lack C.M., Morgan D., Roberts D.C.S., and Jones S.R. Reduced dopamine terminal function and insensitivity to cocaine following cocaine binge self-administration and deprivation. Neuropsychopharmacology 30 (2005) 1455-1463
105. Mathieu-Kia A.-M., and Besson M.-J. Repeated administration of cocaine, nicotine and ethanol: effects on preprodynorphin, preprotachykinin A and preproenkephalin mRNA expression in the dorsal and the ventral striatum of the rat. Mol Brain Res 54 (1998) 141-151
106. Matthews R.T., and German D.C. Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine. Neuroscience 11 3 (1984) 617-625
107. Matsuzawa S., Suzuki T., Misawa M., and Nagase H. Different roles of μ-, delta- and kappa-opioid receptors in ethanol-associated place preference in rats exposed to conditioned fear stress. Eur J Pharmacol 368 (1999) 9-16
108. McFarland K., Lapish C.C., and Kalivas P.W. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J Neurosci 23 8 (2003) 3531-3537
109. McFarland K., Davidge S.B., Lapish C.C., and Kalivas P.W. Limbic and motor circuitry underlying footshock-induced reinstatement of cocaine-seeking behavior. J Neurosci 24 7 (2004) 1551-1560
110. McGeorge A.J., and Faull R.L. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience 29 (1989) 503-537
111. McLaughlin J.P., Marton-Popovici M., and Chavkin C. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 23 (2003) 5674-5683
112. McLaughlin J.P., Land B.B., Li S., Pintar J.E., and Chavkin C. Prior activation of kappa opioid receptors by U50, 488 mimics repeatd forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacology 31 (2006) 787-794
113. Meiergerd S.M., Schenk J.O., and Sorg B.A. Repeated cocaine and stress increase dopamine clearance in the rat medial prefrontal cortex. Brain Res 773 (1997) 203-207
114. Melendez R.I., Rodd Z.A., McBride W.J., and Murphy J.M. Involvement of the mesopallidal dopamine system in ethanol reinforcement. Alcohol 32 2 (2004) 137-144
115. Mello N.K., and Negus S.S. Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J Pharmacol Exp Ther 286 (1998) 812-824
116. Meshul C.K., and McGinty J.F. Kappa opioid receptor immunoreactivity in the nucleus accumbens and caudate-putamen is primarily associated with synaptic vesicles in axons. Neuroscience 96 (2000) 91-99
117. Metcalf M.D., and Coop A. Kappa opioid antagonists: past successes and future prospects. AAPS 7 (2005) E704-E722
118. Mitchell J.M., Liang M.T., and Fields H.L. A single injection of the kappa opioid antagonist norbinaltorphimine increases ethanol consumption in rats. Psychopharmacology 182 (2005) 384-392
119. Mitrovic I., and Napier T.C. Electrophysiological demonstration of mu, delta and kappa opioid receptors in the ventral pallidum. J Pharmacol Exp Ther 272 (1995) 1260-1270
120. Mitrovic I., and Napier T.C. Substance P attenuates and DAMGO potentiates amygdala glutamatergic neurotransmission within the ventral pallidum. Brain Res 792 (1998) 193-206
121. Mitrovic I., and Napier T.C. Mu and kappa opioid agonists modulate ventral tegmental area input to the ventral pallidum. Eur J Neurosci 15 (2002) 257-268
122. Mogenson G.J., and Yang C.R. The contribution of basal forebrain to limbic-motor integration and the mediation of motivation to action. Adv Exp Med Biol 295 (1991) 267-290
123. Morgan D., Liu Y., and Roberts D.C. Rapid and persistent sensitization to the reinforcing effects of cocaine. Neuropsychopharmacology 31 1 (2006) 121-128
124. Mucha R.F., and Herz A. Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology 86 (1985) 274-280
125. Napier T.C., and Mitrovic I. Opioid modulation of ventral pallidal inputs. In: McGinty J. (Ed). Advancing from the Ventral Striatum to the Extended Amygdala: Implications for Neuropsychiatry and Drug Abuse. Annuals of the New York Academy of Sciences, New York, NY Vol. 877 (1999) 176-201
126. Napier T.C., and Potter P.E. Dopamine in the rat ventral pallidum/substantia innominata: biochemical and electrophysiological studies. Neuropharmacology 28 (1989) 757-760
127. Negus S.S. Effects of the kappa opioid agonist U50, 488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys. Psychopharmacology 176 (2004) 204-213
128. Negus S.S., Mello N.K., Portoghese P.S., and Lin C.E. Effects of kappa opioids on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther 282 (1997) 44-55
129. Newton S.S., Thome J., Wallace T.L., Shirayama Y., Schlesinger L., Sakai N., et al. Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J Neurosci 22 (2002) 10883-10890
130. Ng J.P., Menacherry S.D., Liem B.J., Anderson D., Singer M., and Justice Jr. J.B. Increased stimulated release and uptake of dopamine in nucleus accumbens after repeated cocaine administration as measured by in vivo voltammetry. J Neurochem 56 (1991) 1485-1492
131. Nicol B., Rowbotham D.J., and Lambert D.G. μ and κ-opioids inhibit K+ evoked glutamate release from rat cerebrocortical slices. Neurosci Lett 218 (1996) 79-82
132. Nylander I., Hyytia P., Forsander O., and Terenius L. Differences between alcohol-preferring (AA) and alcohol-avoiding (ANA) rats in the prodynorphin and proenkephalin systems. Alcohol Clin Exp Res 18 5 (1994) 1272-1279
133. O'Brien C.P. Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry 162 (2005) 1423-1431
134. Olds M.E., and Fobes J.L. The central basis of motivation: intracranial self-stimulation studies. Annu Rev Psychol 32 (1981) 523-574
135. Olianas M.C., Concas D., and Onali P. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors. Br J Pharmacol 147 4 (2006) 360-370
136. Oswald L.M., and Wand G.S. Opioids and alcoholism. Physiol Behav 81 (2004) 339-358
137. Packard M.G., and Knowlton B.J. Learning and memory functions of the basal ganglia. Annu Rev Neurosci 25 (2002) 563-593
138. Peckys D., and Landwehrmeyer G.B. Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study. Neuroscience 88 4 (1999) 1093-1135
139. Pfieffer A., Brantl V., Herz A., and Emrich H.M. Psychotomimesis mediated by 6 opioid receptors. Science 233 4765 (1986) 774-776
140. Pickel V.M., and Sesack C.J. Cellular substrates for interactions between dynorphin terminals and dopamine dendrites in rat ventral tegmental area and substantia nigra. Brain Res 602 2 (1993) 275-289
141. Pliakas A.M., Carlson R.R., Neve R.L., Konradi C., Nestler E.J., and Carlezon W.A. Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens. J Neurosci 21 18 (2001) 7397-7403
142. Ploj K., Roman E., Gustavsson L., and Nylander I. Basal levels and alcohol-induced changes in nociceptin/orphanin FQ, dynorphin, and enkephalin levels in C57BL/6J mice. Brain Res Bull 53 2 (2000) 219-226
143. Porsolt R.D., Le Pichon M., and Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 266 (1977) 730-732
144. Portoghese P.S., Lin C.E., Farouz-Grant F., and Takemori A.E. Structure-activity relationship of N17′-substituted norbinaltorphimine congeners. Role of the N17′ basic group in the interaction with a putative address subsite on the kappa opioid receptor. J Med Chem 37 (1994) 1495-1500
145. Przewlocka B., Turchan J., Lason W., and Przewlocki R. Ethanol withdrawal enhances the prodynorphin system activity in the rat nucleus accumbens. Neurosci Lett 238 (1997) 13-16
146. Przewlocki R., Lason W., Hollt V., Silberring J., and Herz A. The influence of chronic stress on multiple opioid peptide systems in the rat: pronounced effects upon dynorphin in spinal cord. Brain Res 413 2 (1987) 213-219
147. Ranaldi R., Pocock D., Zereik R., and Wise R.A. Dopamine fluctuations in the nucleus accumbens during maintenance, extinction, and reinstatement of intravenous d-amphetamine self-administration. J Neurosci 19 (1999) 4102-4109
148. Rawls S.M., and McGinty J.F. l-trans-pyrrolidine-2, 4-dicarboxylic acid-evoked striatal glutamate levels are attenuated by calcium reduction, tetrodotoxin, and glutamate receptor blockade. J Neurochem 68 (1997) 1553-1563
149. Rawls S.M., McGinty J.F., and Terrian D.M. Presynaptic kappa-opioid and muscarinic receptors inhibit the calcium-dependent component of evoked glutamate release from striatal synaptosomes. J Neurochem 73 (1999) 1058-1065
150. Rebec G.V., and Sun W. Neuronal substrates of relapse to cocaine-seeking behavior: role of prefrontal cortex. J Exp Anal Behav 84 3 (2005) 653-666
151. Reid M., Herrera-Marschitz M., Hokfelt T., Terenius L., and Ungerstedt U. Differential modulation of striatal dopamine release by intranigral injection of gamma-aminobutyric acid (GABA), dynorphin A and substance P. Eur J Pharmacol 147 (1988) 411-420
152. Ritz M.C., Lamb R.J., Goldberg S.R., and Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237 (1987) 1219-1223
153. Robbins T.W., and Everitt B.J. Drug addiction: bad habits add up. Nature 398 (1999) 567-570
154. Roberts A.J., McDonald J.S., Heyser C.J., Kieffer B.L., Matthes H.W.D., Koob G.F., et al. Kappa-opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther 293 (2000) 1002-1008
155. Robinson T.E., and Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 18 (1993) 247-291
156. Robinson T.E., and Berridge K.C. Incentive-sensitization and addiction. Addiction 96 (2001) 103-114
157. Romualdi P., Lesa G., and Ferri S. Chronic opiate agonists down-regulate prodynorphin gene expression in rat brain. Brain Res 563 (1991) 132-136
158. Rosin A., Lindholm S., Franck J., and Georgieva J. Downregulation of kappa opioid receptor mRNA levels by chronic ethanol and repetitive cocaine in rat ventral tegmentum and nucleus accumbens. Neurosci Lett 275 (1999) 1-4
159. Roth B.L., Baner K., Westkaemper R., Siebert D., Rice K.C., Steinberg S., et al. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci 99 (2002) 11934-11939
160. Sbrenna S., Marti M., Morari M., Calo G., Guerrini R., Bean L., et al. l-Glutamate and γ-aminobutyric acid efflux from rat certebrocortical synaptosomes: modulation by kappa- and mu- but not delta- and opioid receptor like-1 receptors. J Pharmacol Exp Ther 291 (1999) 1365-1371
161. Schenk S., Partridge B., and Shippenberg T.S. U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology 1444 4 (1999) 339-346
162. Schenk S., Partridge B., and Shippenberg T.S. Reinstatement of extinguished drug-taking behavior in rats: effect of the kappa-opioid receptor agonist, U69593. Psychopharmacology 151 1 (2000) 85-90
163. Schenk S., Partridge B., and Shippenberg T.S. Effects of the kappa-opioid receptor agonist, U69593, on the development of sensitization and on the maintenance of cocaine self-administration. Neuropsychopharmacology 24 4 (2001) 441-450
164. Schmidt P., Schroder H., Maderspach K., and Staak M. Immunohistochemical localization of kappa opioid receptors in the human frontal cortex. Brain Res 654 (1994) 223-233
165. Schultz W. Getting formal with dopamine and reward. Neuron 36 (2002) 241-263
166. Segal D.S., and Kuczenski R. Repeated cocaine administration induces behavioral sensitization and corresponding decreased extracellular dopamine responses in caudate and accumbens. Brain Res 577 2 (1992) 351-355
167. Shippenberg T.S., and Herz A. Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of mu- and kappa-opioid agonists. Brain Res 436 (1987) 169-172
168. Shippenberg T.S., and Herz A. Motivational effects of opioids: influence of D-1 versus D-2 receptor antagonists. Eur J Pharmacol 151 (1988) 233-242
169. Shippenberg T.S., Stein C., Huber A., Millan M.J., and Herz A. Motivational effects of opioids in an animal model of prolonged inflammatory pain: alteration in the effects of kappa-but not of mu-receptor agonists. Pain 35 (1988) 179-186
170. Shippenberg T.S., Bals-Kubik R., Huber A., and Herz A. Neuroanatomical substrates mediating the aversive effects of D-1 dopamine receptor antagonists. Psychopharmacology 103 (1991) 209-214
171. Shippenberg T.S., Bals-Kubik R., and Herz A. Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors. J Pharmacol Exp Ther 265 (1993) 53-59
172. Shippenberg T.S., LeFevour A., and Heidbreder C. Kappa-opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine. J Pharmacol Exp Ther 276 2 (1996) 545-554
173. Shippenberg T.S., Chefer V.I., Zapata A., and Heidbreder C.A. Modulation of the behavioral and neurochemical effects of psychostimulants by kappa-opioid receptor systems. Ann N Y Acad Sci 937 (2001) 50-73
174. Shirayama Y., Ishida H., Iwata M., Hazama G.I., Kawahara R., and Duman R.S. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem 90 (2004) 1258-1268
175. Simonato M., and Romualdi P. Dynorphin and epilepsy. Prog Neurobiol 50 (1996) 557-583
176. Smith J.E., Co C., Yin X., Sizemore G.M., Loguori A., Johnson W.E., et al. Involvement of cholinergic neuronal systems in intravenous cocaine self-administration. Neurosci Biobehav Rev 27 8 (2004) 841-850
177. Solbrig M.V., Adrian R., Baratta J., Piomelli D., and Giuffrida A. Kappa opioid control of seizures produced by a virus in an animal model. Brain 129 (2006) 642-654
178. Spanagel R., Herz A., and Shippenberg T.S. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci 89 (1992) 2046-2050
179. Spanagel R., Almeida O.F., Bartl C., and Shippenberg T.S. Endogenous kappa-opioid systems in opiate withdrawal: role in aversion and accompanying changes in mesolimbic dopamine release. Psychopharmacology 15 1-2 (1994) 121-127
180. Steiner H., and Gerfen C.R. Cocaine-induced c-fos messenger RNA is inversely related to dynorphin expression in striatum. J Neurosci 13 12 (1993) 5066-5081
181. Stogmann E., Zimprich A., Baumgartner C., Aull-Watschinger S., Hollt V., and Zimprich F. A functional polymorphism in the prodynorphin gene promoter is associated with temporal lobe epilepsy. Ann Neurol 51 2 (2002) 260-263
182. Svensson P., and Hurd Y.L. Specific reductions of striatal prodynorphin and D1 dopamine receptor messenger RNAs during cocaine abstinence. Brain Res Mol Brain Res 56 (1998) 162-168
183. Svingos A.L., and Colago E.E.O. Kappa-Opioid and NMDA glutamate receptors are differentially targeted within rat medial prefrontal cortex. Brain Res 946 (2002) 262-271
184. Svingos A.L., Colago E.E.O., and Pickel V.M. Cellular sites for dynorphin activation of 6-opioid receptors in the rat nucleus accumbens shell. J Neurosci 19 (1999) 1804-1813
185. Svingos A.L., Chavkin C., Colago E.E., and Pickel V.M. Major co expression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse 42 (2001) 185-192
186. Tang A.H., and Collins R.J. Behavioral effects of a novel kappa opioid analgesic, U-50488, in rats and rhesus monkeys. Psychopharmacology 85 (1985) 309-314
187. Thompson A.C., Zapata A., Justice J.B., Vaughan R., and Shippenberg T.S. Kappa opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine. J Neurosci 20 (2000) 9333-9340
188. Todtenkopf M.S., Marcus J.F., Portoghese P.S., and Carlezon Jr. W.A. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology 172 (2004) 463-470
189. Turchan J., Przewlocka B., Lason W., and Przewlocki R. Effects of repeated psychostimulant administration on the prodynorphin system activity and kappa opioid receptor density in the rat brain. Neuroscience 85 (1998) 1051-1059
190. Van Bockstaele E.J., Gracy K.N., and Pickel V.M. Dynorphin-immunoreactive terminals in the rat nucleus accumbens: cellular sites for modulation of target neurons and interactions with catecholamine afferents. J Comp Neurol 341 (1994) 1-15
191. Van Bockstaele E.J., Gracy K.N., and Pickel V.M. Dynorphin-immunoreactive neurons in the rat nucleus accumbens: ultrastructure and synaptic input from terminals containing substance P and/or dynorphin. J Comp Neurol 351 (1995) 117-133
192. Vanderschuren L.J., Di Ciano P., and Everitt B.J. Involvement of the dorsal striatum in cue-controlled cocaine seeking. J Neurosci 25 (2005) 8665-8670
193. van Dongen Y.C., Deniau J.M., Pennartz C.M., Galis-de Graaf Y., Voorn P., and Thierry A.M. Anatomical evidence for direct connections between the shell and core subregions of the rat nucleus accumbens. Neuroscience 136 (2005) 1049-1071
194. Von Voigtlander P.F., and Lewis R.A. U-50,488, a selective kappa opioid agonist: comparison to other reputed kappa agonists. Prog Neuro-Psychopharmacol Biol Psychiatry 157 (1982) 151-162
195. Walker B.M., and Koob G.F. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology. (2007, May 2) (Electronic publication ahead of print)
196. Walsh S.L., Strain E.C., Abreu M.E., and Bigelow G.E. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology 157 (2001) 151-162
197. Wang J.Q., Duanais J.B., and McGinty J.F. NMDA receptors mediate amphetamine-induced upregulation of zif/268 and preprodynorphin mRNA expression in rat striatum. Synapse 18 (1994) 343-353
198. Weiss F., Lorang M.T., Bloom F.E., and Koob G.F. Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinant. J Pharmacol Exp Ther 267 (1993) 250-258
199. Weiss F., Parsons L.H., Schulteis G., Hyytia P., Lorang M.T., Bloom F.E., et al. Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats. J Neurosci 16 (1996) 3474-3485
200. Wevers A., Schmidt P., Cserpan E., Cserpan I., Maderspach K., Staak M., et al. Cellular distribution of the mRNA for the kappa-opioid receptor in the human neocortex: a non-isotopic in situ hybridization study. Neurosci Lett 195 (1995) 125-128
201. Williams J.M., and Steketee J.D. Time-dependent effects of repeated cocaine administration on dopamine transmission in the medial prefrontal cortex. Neuropharmacology 48 1 (2005) 51-61
202. Williams K.L., and Woods J.H. Oral ethanol-reinforced responding in rhesus monkeys: effects of opioid antagonists selective for the mu-, kappa-, delta-receptor. Alcohol Clin Exp Res 22 (1998) 1634
203. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 52 (2005) 90-110
204. Willuhn I., Sun W., and Steiner H. Topography of cocaine-induced gene regulation in the rat striatum: relationship to cortical inputs and role of behavioural context. Eur J Neurosci 17 (2003) 1053-1066
205. Wise R.A. Drug-activation of brain reward pathways. Drug Alcohol Depend 51 (1998) 13-22
206. Wise R.A. Dopamine, learning and motivation. Nat Rev Neurosci 5 (2004) 483-494
207. Wise R.A., and Munn E. Withdrawal from chronic amphetamine elevates baseline intracranial self-stimulation thresholds. Psychopharmacology 117 (1995) 130-136
208. Xuei X., Flury L., Bierut L., Crowe R., Dick D., Goate A., et al. Association of the kappa-opioid system with alcohol dependence. Mol Psychiatry 11 (2006) 1016-1024
209. Yin J.C., and Tully T. CREB and the formation of long-term memory. Curr Opin Neurobiol 6 2 (1996) 264-268
210. Yin H.H., Knowlton B.J., and Balleine B.W. Blockade of NMDA receptors in the dorsomedial striatum prevents action-outcome learning in instrumental conditioning. Eur J Neurosci 22 (2005) 505-512
211. Yokoo H., Yamada S., Yoshida M., Tanaka M., and Nishi S. Attenuation of the inhibitory effect of dynorphin on dopamine release in the rat nucleus accumbens by repeated treatment with methamphetamine. Eur J Pharmacol 222 (1992) 43-47
212. Yoshimoto K., McBride W.J., Lumeng L., and Li T.K. Alcohol stimulates the release of dopamine and serotonin in the nucleus accumbens. Alcohol 9 (1992) 17-22
213. You Z.B., Herrera-Marschitz M., and Terenius L. Modulation of neurotransmitter release in the basal ganglia of the rat brain by dynorphin peptides. J Pharmacol Exp Ther 290 (1999) 1307-1315
214. Yuan X.R., Madamba S., and Siggins G.R. Opioid peptides reduce synaptic transmission in the nucleus accumbens. Neurosci Lett 134 (1992) 223-228
215. Yung K.K.L., and Bolam J.P. Localization of dopamine D1 and D2 receptors in the rat neostriatum: synaptic interactions with glutamate and GABA-containing axonal terminals. Synapse 38 (2000) 413-420
216. Záborszky L., Alheid G.F., and Heimer L. Mapping of transmitter-specific connections: simultaneous demonstration of anterograde degeneration and changes in the immunostaining pattern and induced by lesions. J Neurosci Methods 14 (1985) 225-266
217. Zahm D.S., and Heimer L. Specificity in the efferent projections of the nucleus accumbens in the rat: comparison of the rostral pole projection patterns with those of the core and shell. J Comp Neurol 327 (1993) 220-232
218. Zahm D.S., Záborszky L., Alones V.E., and Heimer L. Evidence for the coexistence of glutamate decarboxylase and Met-enkephalin immunoreactivities in axon terminals of rat ventral pallidum. Brain Res 325 (1985) 317-321
219. Zapata A., and Shippenberg T.S. Endogenous kappa opioid receptor systems modulate the responsiveness of mesoaccumbal dopamine neurons to ethanol. Alcohol Clin Exp Res 30 (2006) 592-597
220. Zapata A., Chefer V.I., Ator R., Shippenberg T.S., and Rocha B.A. Behavioural sensitization and enhanced dopamine response in the nucleus accumbens after intravenous cocaine self-administration in mice. Eur J Neurosci 17 (2003) 590-596
221. Zhang Y., Butelman E.R., Schlussman S.D., Ho A., and Kreek M.J. Effect of the endogenous opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology 172 (2004) 422-429
222. Zhou L., Furuta T., and Kaneko T. Chemical organization of projection neurons in the rat accumbens nucleus and olfactory tubercle. Neuroscience 120 (2003) 783-798